Previous 10 | Next 10 |
Francesca's Holdings (NASDAQ: FRAN ) -24% on Q1 results . More news on: Francesca's Holdings Corporation, Medley Management Inc., Brickell Biotech, Inc., Stocks on the move, , Read more ...
MiRagen Therapeutics (NASDAQ: MGEN ) will host a key opinion leader (KOL) call regarding ideopathic pulmonary fibrosis (IPF) on Tuesday, June 23, at 11:00 am ET. More news on: Miragen Therapeutics, Healthcare stocks news, Stocks on the move, Read more ...
BOULDER, Colo., June 16, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it is scheduled to host a key opinion leaders (KOL) call regarding idio...
The following slide deck was published by Miragen Therapeutics in conjunction with this Read more ...
Gainers: Sonoma Pharmaceuticals (NASDAQ: SNOA ) +145% . More news on: Sonoma Pharmaceuticals, Inc., Adaptimmune Therapeutics plc, Phio Pharmaceuticals Corp., Stocks on the move, , Read more ...
ARCA biopharma (NASDAQ: ABIO ) -28% . More news on: ARCA biopharma, Inc., ToughBuilt Industries, Inc., Canopy Growth Corporation, Stocks on the move, , Read more ...
Are These On Your List Of Penny Stocks To Watch Before June 2020? The stock market today is jumping again and so are a number of penny stocks . One thing brought to my attention was the misconception that penny stocks are meant for short-term day trades. Now, before I get to my point, let me ...
BOULDER, Colo., May 26, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that William S. Marshall, Ph.D., President and Chief Executive Officer o...
Miragen Therapeutics, Inc. (MGEN) Q1 2020 Earnings Conference Call May 7, 2020 16:30 ET Company Participants Dan Ferry - Managing Director of LifeSci Advisors Bill Marshall - President & Chief Executive Officer Jason Leverone - Chief Financial Officer Conference Call Parti...
Miragen Therapeutics (NASDAQ: MGEN ): Q1 GAAP EPS of -$0.18 beats by $0.03 . Revenue of $0.83M (+124.3% Y/Y) beats by $0.24M . Press Release More news on: Miragen Therapeutics, Earnings news and commentary, Healthcare stocks news, ,
News, Short Squeeze, Breakout and More Instantly...
Miragen Therapeutics Inc. Company Name:
MGEN Stock Symbol:
NASDAQ Market:
Jonathan Violin, Ph.D., M.B.A. appointed President, CEO and director Barrett Katz, M.D., M.B.A. joins Viridian as Chief Medical Officer Viridian is developing VRDN-001 and VRDN-002 for the treatment of thyroid eye disease Company recently licensed exc...
Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology miRagen expects to file an Investigational New Drug (IND) application for VRD...
Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance mult...